CSPC Pharma Secures NMPA Approval to Launch Clinical Trials for First Recombinant Herpes Zoster Vaccine

Bulletin Express

07/02

CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine, SYS6052.

The vaccine candidate combines varicella-zoster virus glycoprotein E (gE) with a proprietary nanoadjuvant system developed in-house. Pre-clinical studies indicated favorable safety and efficacy profiles, with the optimized antigen–adjuvant pairing designed to elicit robust humoral and cellular immune responses.

SYS6052 targets the prevention of herpes zoster and related complications in adults aged 50 years and above. This marks CSPC Pharma’s first recombinant protein vaccine to reach the clinical-trial stage, representing a significant milestone in the group’s strategic expansion into preventive vaccines.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1168230838"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168230838\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168230838?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168230838","market":"us","top_or_hot":-1,"title":"CSPC Pharma Secures NMPA Approval to Launch Clinical Trials for First Recombinant Herpes Zoster Vaccine","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine, SYS6052.</p>\n<p>The vaccine candidate combines varicella-zoster virus glycoprotein E (gE) with a proprietary nanoadjuvant system developed in-house. Pre-clinical studies indicated favorable safety and efficacy profiles, with the optimized antigen–adjuvant pairing designed to elicit robust humoral and cellular immune responses.</p>\n<p>SYS6052 targets the prevention of herpes zoster and related complications in adults aged 50 years and above. This marks CSPC Pharma’s first recombinant protein vaccine to reach the clinical-trial stage, representing a significant milestone in the group’s strategic expansion into preventive vaccines.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Secures NMPA Approval to Launch Clinical Trials for First Recombinant Herpes Zoster Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Secures NMPA Approval to Launch Clinical Trials for First Recombinant Herpes Zoster Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-02 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine, SYS6052.</p>\n<p>The vaccine candidate combines varicella-zoster virus glycoprotein E (gE) with a proprietary nanoadjuvant system developed in-house. Pre-clinical studies indicated favorable safety and efficacy profiles, with the optimized antigen–adjuvant pairing designed to elicit robust humoral and cellular immune responses.</p>\n<p>SYS6052 targets the prevention of herpes zoster and related complications in adults aged 50 years and above. This marks CSPC Pharma’s first recombinant protein vaccine to reach the clinical-trial stage, representing a significant milestone in the group’s strategic expansion into preventive vaccines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1168230838","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168230838","pubTimestamp":1782990439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团首个重组带状疱疹疫苗获NMPA批准启动临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has received clearance from China’s National Medical Products Administration to initiate clinical trials for its recombinant herpes zoster vaccine, SYS6052.\nThe vaccine candidate combines varicella-zoster virus glycoprotein E (gE) with a proprietary nanoadjuvant system developed in-house. Pre-clinical studies indicated favorable safety and efficacy profiles, with the optimized antigen–adjuvant pairing designed to elicit robust humoral and cellular immune responses.\nSYS6052 targets the prevention of herpes zoster and related complications in adults aged 50 years and above. This marks CSPC Pharma’s first recombinant protein vaccine to reach the clinical-trial stage, representing a significant milestone in the group’s strategic expansion into preventive vaccines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}